In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?

Limited data in this clinical scenario. Per A18 (Lorusso et al., PMID 38521086), 32 patients received ICI as post-progression therapy, 25 of whom received Pembro. I am unable to find in the supplements whether those were patients from the placebo arm or from the pembro arm.

I think if the patient rec...

This would depend on when the patient recurred. If the patient recurred after completion of the dedicated time on A18 then I would consider re-investing in an IO combination. There really is no prospective data on this but current trials are allowing patients with prior IO to enroll in trials. I thi...